Compare IMTE & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMTE | AEMD |
|---|---|---|
| Founded | 2008 | 1984 |
| Country | Australia | United States |
| Employees | N/A | 9 |
| Industry | Consumer Electronics/Appliances | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.1M |
| IPO Year | 2016 | 2008 |
| Metric | IMTE | AEMD |
|---|---|---|
| Price | $0.45 | $0.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 55.2K | ★ 316.9K |
| Earning Date | 10-22-2024 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $0.51 |
| 52 Week High | $1.54 | $5.89 |
| Indicator | IMTE | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 24.61 |
| Support Level | $0.43 | $0.51 |
| Resistance Level | $0.57 | $2.47 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 18.88 | 5.29 |
Integrated Media Technology Ltd is mainly engaged in the business of manufacture and sale of nano-coated plates for filters, the manufacture and sale of electronic glass, Halal certification and distribution of Halal products, and new energy products and services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.